Timor-LesteTuberculosis profile
Population  2014 1.2 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.1 (0.76–1.5) 94 (66–126)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 9.5 (4.9–16) 820 (426–1 340)
Incidence  (includes HIV+TB) 5.8 (4.8–6.9) 498 (411–594)
Incidence (HIV+TB only) 0.057 (0.042–0.073) 4.9 (3.7–6.3)
         
Case detection, all forms (%) 63 (53–77)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.2 (1.9–2.6) 16 (14–18)
MDR-TB cases among notified pulmonary
TB cases
67 (58–80) 32 (28–35)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 1 838   78
Pulmonary, clinically diagnosed 1 222    
Extrapulmonary 519    
       
Total new and relapse 3 657    
Previously treated, excluding relapses 121    
Total cases notified 3 778    
Among 3 579 new cases:
390 (11%) cases aged under 15 years; male:female ratio: 1.2
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB   198 (99%) 198
Laboratory-confirmed RR-/MDR-TB cases     3
Patients started on MDR-TB treatment ***     3
TB/HIV 2014 Number (%)
TB patients with known HIV status 2 054 (54)
HIV-positive TB patients 24 (1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 24 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 24 (100)
HIV-positive people screened for TB 142  
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (84) 3 718
Previously treated cases, excluding relapse, registered in 2013 (91) 11
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (75) 4
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 1.6
Culture (per 5 million population)  
Drug susceptibility testing (per 5 million population)  
Sites performing Xpert MTB/RIF 2
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 1.6
% Funded domestically 27%
% Funded internationally 73%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-31 Data: www.who.int/tb/data